Lund, Sweden, May 8, 2020 - Xintela has been granted 1 million SEK from Vinnova in the call for ” Innovations in the wake of the crisis - Restructuring of society, operations and production in the wake of the corona epidemic.”. The grant concerns the funding of a preclinical study to evaluate Xintela's stem cells for the treatment of Covid-19 patients with the fatal disease condition ARDS (Acute Respiratory Distress Syndrome).
The project, which is partly financed by Vinnova, intends to evaluate safety and efficacy of Xintela's Mesenchymal Stem Cells (XSTEM®) in a preclinical model for ARDS, a disease condition that can affect Covid-19 patients. ARDS is a very serious and difficult-to-treat lung disease that requires oxygen therapy, often intensive care with a respirator, and leads to many deaths.
Xintela's stem cells will be tested in a validated ARDS model in collaboration with Associate Professor Sandra Lindstedt Ingemansson at the Department of Cardiothoracic Surgery and Transplantation at Skåne University Hospital in Lund. If the study is successful, the results will form the basis for an application to the Swedish Medical Products Agency to carry out clinical studies on Covid-19 patients with severe and deadly lung symptoms.
Xintela's application received a maximum grant in tough competition where 18 applications out of a total of 270 were approved. In total, SEK 10 million was available, with a maximum amount per application of SEK 1 million.
- To meet the huge need for a life-saving treatment for Covid-19 patients, we are expanding our development work on our selected and quality-assured stem cells. Stem cells have the potential to treat Covid-19 patients through the cells' anti-inflammatory and immunomodulatory effects by reducing the severe cytokine storm that affects the seriously ill patients. The fact that our project was approved in competition with a large number of applications is an exciting quality stamp for our efforts, says Xintela's CEO Evy Lundgren-Åkerlund.
This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the below contact, for publication on the 8th of May 2020.
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
223 81 Lund, Sweden
Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cells and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, firstname.lastname@example.org.
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
CEO Evy Lundgren-Åkerlund presents the company at Aktiespararnas Småbolagsdagarna 2022 (in Swedish).
Targinta's CEO Per Norlén presents the company at Aktiespararnas Småbolagsdagarna 2022 (in Swedish).
CEO Evy Lundgren-Åkerlund presents the company at BioStock Life Science Spring Summit 2022.
BioStock interview with Xintela's CMO and board member Sven Kili.
BioStock was given the opportunity to interview Sven Kili in connection with his visit to Sweden for board and strategy work in Xintela.
Dr. Marcus Keep comments on Xintelas glioblastoma project.
Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.
Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.
In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.
See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.
See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).
See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.
Investor presentation from Lund - Jan 27
Interview with Xintelas CEO